Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Samantha DrennanGiorgia ChiodinAnnalisa D'AvolaIan TracyPeter W M Johnson Livio Trentin Andrew J SteeleGraham PackhamFreda K StevensonFrancesco Forconi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

This specific IgM increase in patients underpins the key role of tissue-based engagement with antigen in CLL, confirms the inhibitory action of ibrutinib, and reveals dynamic adaptability of CLL cells to precision monotherapy.See related commentary by Burger, p. 2372.

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
randomized controlled trial
induced apoptosis
clinical trial
cell proliferation
study protocol
cell therapy